Estimated Average Glucose (eAG): How HbA1c Becomes a Daily Number

What estimated average glucose actually is

Estimated average glucose (eAG) is a calculated value that translates your HbA1c percentage into average blood glucose in mg/dL — the same units displayed on a glucose meter or CGM. It reflects typical blood sugar over roughly the past two to three months, weighted toward the most recent four to six weeks because younger red blood cells are more abundant. The formula was validated in the ADAG study (Nathan DM et al., 2008, Diabetes Care) and is endorsed by the American Diabetes Association. Higher eAG signals higher average glucose exposure and, over time, greater stress on blood vessels, nerves, and kidneys; lower eAG signals lower average exposure.

Why HbA1c needs a daily-glucose translation

HbA1c is reported as a percentage — the share of hemoglobin molecules that have had glucose chemically attached to them during the roughly 120-day lifespan of a red blood cell. That percentage is a precise, standardized lab value, but it is opaque to anyone who uses a glucose meter or CGM, where readings appear in mg/dL. A result of 6.0% carries little intuitive weight; 125.5 mg/dL can be directly compared to a fingerstick reading taken after breakfast. eAG performs that unit translation, making HbA1c actionable in the language of daily life.

The translation also surfaces an important weighting story. Because younger red blood cells are more abundant in circulation at any given moment, the most recent four to six weeks of glucose exposure contribute more to HbA1c — and therefore to eAG — than weeks ten to twelve ago. A month of consistent dietary change or a short course of glucocorticoids will begin to move eAG before the full three-month window has elapsed, even though the signal is still an average. Understanding this recency weighting helps explain why eAG can shift meaningfully between quarterly draws without requiring a full 120-day wait.

One individual-level nuance remains: the HbA1c-to-glucose relationship is derived from population averages. Some people glycate hemoglobin at a slightly higher or lower rate than the formula assumes, meaning their eAG may modestly overstate or understate true average glucose. Patterns across repeat tests and clinical context always carry more weight than any single number.

The eAG formula, worked through step by step

The ADAG study formula, endorsed by the ADA, is:

• eAG (mg/dL) = 28.7 × HbA1c (%) − 46.7
• eAG (mmol/L) = 1.59 × HbA1c (%) − 2.59

Source: Nathan DM et al., Diabetes Care, 2008, ADAG study group. HbA1c does not require fasting; eAG inherits the same non-fasting draw standard.

Worked example — HbA1c 6.0%

eAG = (28.7 × 6.0) − 46.7 = 172.2 − 46.7 = 125.5 mg/dL. The HbA1c percentage felt abstract; 125.5 mg/dL is directly comparable to a fingerstick reading, clarifying the daily-life glucose exposure. This result sits in the upper normal range.

Worked example — HbA1c 7.0%

eAG = (28.7 × 7.0) − 46.7 = 200.9 − 46.7 = 154.2 mg/dL. This falls in the diabetes management range, where daily glucose exposure is meaningfully elevated and clinical review is warranted.

Validity caveat

eAG is unreliable when HbA1c is distorted by conditions that alter red blood cell lifespan — hemolytic anemia, iron deficiency, and hemoglobin S/C variants can all cause HbA1c to read falsely high or low. In these cases, fructosamine or glycated albumin provide alternative average-glucose estimates that do not depend on red blood cell turnover.

Reading your eAG number in context

eAG inherits its reference categories directly from HbA1c, because it is a mathematical conversion of that value. The cutoffs below reflect standard ADA diagnostic thresholds translated through the ADAG formula. They are population-derived reference points, not personalized targets — a competitive athlete, a person who is pregnant, and an older adult managing cardiovascular disease will not share the same goals.

• Preventive-optimal range (~90–100 mg/dL, HbA1c ≈ 4.8–5.1%): Cited in some cardiometabolic-prevention literature as a lower-risk zone. Not a formal diagnostic category; context and individual history matter.
• Normal (<117 mg/dL, HbA1c <5.7%): Below the prediabetes threshold. Average glucose exposure is within the range seen in people without diabetes.
• Prediabetes range (~117–137 mg/dL, HbA1c 5.7–6.4%): Average glucose is elevated above normal but below the diabetes diagnostic cutoff. A signal for closer monitoring and lifestyle review.
• Diabetes threshold (≥140 mg/dL, HbA1c ≥6.5%): At or above the level used as one diagnostic criterion for diabetes when confirmed on repeat testing. Clinical evaluation is indicated.

Two important caveats apply to any eAG result. First, conditions that alter red blood cell lifespan — hemolytic anemia, iron deficiency, hemoglobin variants such as HbS or HbC — can cause HbA1c to read falsely high or low, making eAG unreliable in those individuals. Second, eAG is a calculated estimate, not a direct measurement, and is not itself a diagnostic tool. Treat it as a conversation starter with your clinician, not a verdict.

What moves estimated average glucose over months

Dietary fiber and post-meal glucose kinetics

Fiber slows digestion by forming a gel-like barrier in the intestine, blunting the post-meal glucose peak and giving insulin a more manageable load to clear. Over weeks, consistently lower post-meal excursions reduce the average glucose that feeds into HbA1c and eAG. Meal order also changes absorption kinetics: starting with vegetables and protein before starch slows gastric emptying and flattens the glucose curve. Cooking and cooling starchy foods increases resistant starch content, further softening the glycemic response.

Post-meal movement and GLUT4

Skeletal muscle contraction opens GLUT4 glucose transporters independently of insulin, pulling glucose into muscle within minutes of activity. Even ten minutes of light movement after a meal meaningfully lowers the post-meal glucose peak. Over time, regular training builds mitochondrial capacity and improves insulin sensitivity, reducing the area under the daily glucose curve and, by extension, eAG.

Sleep and cortisol

Short sleep and late circadian timing reduce insulin sensitivity and raise next-day glucose responses. Chronic psychological stress elevates cortisol and catecholamines, raising fasting glucose and amplifying post-meal excursions. These effects accumulate over weeks and are reflected in eAG.

Medications and conditions that confound eAG

Glucocorticoids and some antipsychotics raise average glucose directly. Thyroid dysfunction, Cushing physiology, and sleep apnea can do the same. Anything that shortens red blood cell lifespan — hemolysis, significant blood loss, dialysis — lowers HbA1c and therefore eAG independently of true glucose levels. Iron deficiency may raise HbA1c until corrected. Hemoglobin variants can cause certain HbA1c assay methods to read falsely high or low, making eAG unreliable in those individuals regardless of actual glucose control.

Markers that read eAG in context

• HbA1c — the source measurement from which eAG is derived; HbA1c provides the standardized glycated-hemoglobin value and eAG is its unit-translated form.
• Glucose — fasting plasma glucose provides a real-time single-point reading that complements eAG's three-month average; together they help identify whether post-meal spikes or fasting drift is driving average glucose up.
• Insulin — fasting insulin alongside eAG identifies whether elevated average glucose reflects insulin resistance (high insulin), relative insulin deficiency, or compensatory hyperinsulinemia before glucose rises.
• Fructosamine — a two-to-three-week glycation marker useful when HbA1c is unreliable due to hemolytic anemia, pregnancy, or hemoglobin variants; a cross-check for eAG when the underlying HbA1c may be distorted.
• Glycation gap — the discordance between HbA1c-estimated glucose and measured glucose; a large gap may indicate that eAG is overstating or understating true average glucose for a given individual due to individual variation in glycation rate.

When to retest eAG after a change

eAG is a mathematical conversion of HbA1c, which integrates glucose over approximately three months with the most recent four to six weeks weighted most heavily. Retesting more frequently than twelve weeks does not provide meaningfully different information — the integration window is fixed by red blood cell lifespan (~120 days). After a dietary, medication, or lifestyle change, pace the retest at eight to twelve weeks to allow enough of the new signal to accumulate.

For individuals with prediabetes or in active glucose management, quarterly retesting (every three months) provides actionable resolution and aligns with standard clinical practice. Using the same laboratory is preferred — NGSP-certified HbA1c methods are standardized, but switching platforms can introduce small systematic differences that complicate trend interpretation.

If HbA1c is unreliable for a given individual due to a hemoglobin variant or anemia, eAG cannot be meaningfully calculated from it. In those cases, fructosamine is the appropriate alternative for tracking average glucose over time.

When eAG results warrant a clinician conversation

Glucose management rewards curiosity. Trending eAG over months helps catch drift early, course-correct faster, and align habits with how your body actually responds. Pair the numbers with lived experience: how you feel after certain meals, how you recover from training, whether a stressful stretch at work quietly raises your baseline. When lab trends and daily data move together, the signal becomes clear.

Bring your results to a clinician if eAG is at or above the prediabetes threshold (~117 mg/dL) on repeat testing, if it is rising across consecutive draws even within the normal range, if it does not match your fingerstick or CGM readings (which may indicate an HbA1c reliability issue), or if you are managing a condition — pregnancy, anemia, a hemoglobin variant — that makes eAG interpretation uncertain. A single elevated result in the context of illness or a short medication course is different from a sustained pattern; persistence is what drives risk.

Looking at eAG in isolation gives you one scene. Combining it with HbA1c, fasting glucose, insulin, and — where relevant — fructosamine gives you the full picture: where average glucose sits, what is driving it, and whether the trend is moving in the right direction. That is the foundation of evidence-based, personalized metabolic health. Superpower is built around that approach — if you want to understand what your numbers are telling you, explore how we think about it at our manifesto.